Argentina's ANMAT has prohibited the use, marketing, and distribution throughout the country of two specific products: "DICLOFENAC HLB / DICLOFENAC SODIUM" and "MORPHINE 1% HLB / MORPHINE," both manufactured by a specific company.
This measure was taken after receiving a complaint about a mix-up or cross-contamination between these products, which represents a quality deviation classified as critical by the Department of Post-Marketing Surveillance and Regulatory Actions (DVPCAR) of the National Institute of Drugs.
The incident poses a significant risk to public health, as cross-contamination can affect the safety and efficacy of the drugs involved.
**WHOM DOES THIS IMPACT? **
The direct impact is on patients, the manufacturing company, and the health system.
**CONCLUSION: **
The ANMAT prohibition on these products has a significant impact due to the significant risk to public health caused by cross-contamination. This action seeks to protect public health and ensure that the products meet the quality and safety standards required by Argentine health regulations.
Regulatory Impact
| Impact Type | Status |
|---|---|
| Top Priority | |
| Type Certificate | |
| Spectrum Bands | |
| Import Changes (HS Codes) | |
| Standard Changes | |
| Product Changes | |
| Label Changes |